Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Krystal Biotech Analyst Ratings and Price Targets | NASDAQ:KRYS | Benzinga
Krystal Biotech Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Krystal Biotech Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
Guggenheim
Chardan Capital
HC Wainwright & Co.
Jefferies
1calculated from analyst ratings
Analyst Ratings for Krystal Biotech
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/16/2025 | Buy Now | — | Citigroup | Yigal Nochomovitz53% | $215 → $155 | Maintains | Neutral | Get Alert |
| 05/07/2025 | Buy Now | — | Guggenheim | Debjit Chattopadhyay50% | $195 → $189 | Maintains | Buy | Get Alert |
| 05/07/2025 | Buy Now | — | Chardan Capital | Geulah Livshits44% | $219 → $219 | Maintains | Buy | Get Alert |
| 05/06/2025 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $240 → $240 | Reiterates | Buy → Buy | Get Alert |
| 04/29/2025 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $221 → $240 | Maintains | Buy | Get Alert |
| 04/28/2025 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $221 → $240 | Maintains | Buy | Get Alert |
| 03/05/2025 | Buy Now | — | Jefferies | Roger Song33% | → $245 | Initiates | → Buy | Get Alert |
| 02/28/2025 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $221 → $221 | Reiterates | Buy → Buy | Get Alert |
| 02/20/2025 | Buy Now | — | Citigroup | Yigal Nochomovitz53% | $206 → $215 | Maintains | Neutral | Get Alert |
| 02/20/2025 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer50% | → $215 | Reiterates | Overweight → Overweight | Get Alert |
| 02/20/2025 | Buy Now | — | Chardan Capital | Geulah Livshits44% | $212 → $218 | Maintains | Buy | Get Alert |
| 02/19/2025 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $221 → $221 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2024 | Buy Now | — | Chardan Capital | Geulah Livshits44% | $212 → $212 | Maintains | Buy | Get Alert |
| 12/18/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $221 → $221 | Reiterates | Buy → Buy | Get Alert |
| 12/13/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $221 → $221 | Reiterates | Buy → Buy | Get Alert |
| 12/12/2024 | Buy Now | — | Chardan Capital | Geulah Livshits44% | $212 → $212 | Maintains | Buy | Get Alert |
| 12/10/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $221 → $221 | Reiterates | Buy → Buy | Get Alert |
| 11/05/2024 | Buy Now | — | Citigroup | Yigal Nochomovitz53% | $204 → $206 | Maintains | Neutral | Get Alert |
| 11/05/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $221 → $221 | Reiterates | Buy → Buy | Get Alert |
| 09/11/2024 | Buy Now | — | Stifel | Dae Gon Ha46% | $204 → $220 | Maintains | Buy | Get Alert |
| 08/29/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer50% | — | Reiterates | → Overweight | Get Alert |
| 08/29/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $221 → $221 | Reiterates | Buy → Buy | Get Alert |
| 08/28/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $200 → $221 | Maintains | Buy | Get Alert |
| 08/12/2024 | Buy Now | — | Evercore ISI Group | Gavin Clark-Gartner37% | $201 → $206 | Maintains | Outperform | Get Alert |
| 08/06/2024 | Buy Now | — | Citigroup | Yigal Nochomovitz53% | $195 → $204 | Downgrade | Buy → Neutral | Get Alert |
| 08/05/2024 | Buy Now | — | Chardan Capital | Geulah Livshits44% | $153 → $208 | Maintains | Buy | Get Alert |
| 08/05/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 05/06/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 04/22/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 04/16/2024 | Buy Now | — | Stifel | Dae Gon Ha46% | $178 → $204 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2024 | Buy Now | — | Citigroup | Yigal Nochomovitz53% | $160 → $195 | Maintains | Buy | Get Alert |
| 02/27/2024 | Buy Now | — | Guggenheim | Debjit Chattopadhyay50% | $130 → $175 | Maintains | Buy | Get Alert |
| 12/13/2023 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer50% | $160 → $180 | Maintains | Overweight | Get Alert |
| 11/20/2023 | Buy Now | — | Goldman Sachs | Andrea Tan37% | → $160 | Initiates | → Buy | Get Alert |
| 11/07/2023 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer50% | → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 10/24/2023 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer50% | → $160 | Initiates | → Overweight | Get Alert |
| 10/12/2023 | Buy Now | — | Citigroup | Carly Kenselaar72% | → $160 | Initiates | → Buy | Get Alert |
| 09/07/2023 | Buy Now | — | Berenberg | Caroline Palomeque59% | → $154 | Initiates | → Buy | Get Alert |
| 08/08/2023 | Buy Now | — | Chardan Capital | Geulah Livshits44% | $148 → $153 | Maintains | Buy | Get Alert |
| 08/07/2023 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | → $139 | Reiterates | Buy → Buy | Get Alert |
| 07/27/2023 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | → $139 | Reiterates | Buy → Buy | Get Alert |
| 07/03/2023 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | → $139 | Reiterates | → Buy | Get Alert |
| 05/25/2023 | Buy Now | — | B of A Securities | Alec Stranahan33% | $118 → $140 | Maintains | Buy | Get Alert |
| 05/24/2023 | Buy Now | — | Stifel | Dae Gon Ha46% | $102 → $145 | Maintains | Buy | Get Alert |
| 05/22/2023 | Buy Now | — | Guggenheim | Debjit Chattopadhyay50% | $101 → $130 | Maintains | Buy | Get Alert |
| 05/22/2023 | Buy Now | — | Goldman Sachs | Madhu Kumar72% | $135 → $155 | Maintains | Buy | Get Alert |
| 05/22/2023 | Buy Now | — | Chardan Capital | Geulah Livshits44% | $133 → $148 | Maintains | Buy | Get Alert |
| 05/22/2023 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $119 → $139 | Maintains | Buy | Get Alert |
| 05/22/2023 | Buy Now | — | B of A Securities | Alec Stranahan33% | $105 → $118 | Maintains | Buy | Get Alert |
| 05/07/2023 | Buy Now | — | Goldman Sachs | Madhu Kumar72% | → $135 | Maintains | Buy | Get Alert |
| 04/18/2023 | Buy Now | — | Stifel | Dae Gon Ha46% | → $102 | Initiates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | — | Guggenheim | Debjit Chattopadhyay50% | → $101 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | → $119 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | — | Goldman Sachs | Madhu Kumar72% | $79 → $124 | Upgrade | Neutral → Buy | Get Alert |
| 02/28/2023 | Buy Now | — | Chardan Capital | Geulah Livshits44% | → $133 | Reiterates | → Buy | Get Alert |
| 11/08/2022 | Buy Now | — | Chardan Capital | Geulah Livshits44% | $130 → $133 | Maintains | Buy | Get Alert |
| 11/07/2022 | Buy Now | — | Goldman Sachs | Madhu Kumar72% | $74 → $79 | Maintains | Neutral | Get Alert |
| 11/07/2022 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $107 → $119 | Maintains | Buy | Get Alert |
| 08/25/2022 | Buy Now | — | Goldman Sachs | Madhu Kumar72% | → $74 | Downgrade | Buy → Neutral | Get Alert |
| 08/09/2022 | Buy Now | — | Chardan Capital | Geulah Livshits44% | $137 → $130 | Maintains | Buy | Get Alert |
| 08/08/2022 | Buy Now | — | Goldman Sachs | Madhu Kumar72% | $78 → $74 | Maintains | Buy | Get Alert |
| 05/24/2022 | Buy Now | — | Goldman Sachs | Madhu Kumar72% | $91 → $78 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Krystal Biotech (KRYS) stock?
The latest price target for Krystal Biotech (NASDAQ:KRYS) was reported by Citigroup on May 16, 2025. The analyst firm set a price target for $155.00 expecting KRYS to rise to within 12 months (a possible 16.71% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Krystal Biotech (KRYS)?
The latest analyst rating for Krystal Biotech (NASDAQ:KRYS) was provided by Citigroup, and Krystal Biotech maintained their neutral rating.
When was the last upgrade for Krystal Biotech (KRYS)?
The last upgrade for Krystal Biotech Inc happened on February 28, 2023 when Goldman Sachs raised their price target to $124. Goldman Sachs previously had a neutral for Krystal Biotech Inc.
When was the last downgrade for Krystal Biotech (KRYS)?
The last downgrade for Krystal Biotech Inc happened on August 6, 2024 when Citigroup changed their price target from $195 to $204 for Krystal Biotech Inc.
When is the next analyst rating going to be posted or updated for Krystal Biotech (KRYS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Krystal Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Krystal Biotech was filed on May 16, 2025 so you should expect the next rating to be made available sometime around May 16, 2026.
Is the Analyst Rating Krystal Biotech (KRYS) correct?
While ratings are subjective and will change, the latest Krystal Biotech (KRYS) rating was a maintained with a price target of $215.00 to $155.00. The current price Krystal Biotech (KRYS) is trading at is $132.81, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
